查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703462

卡馬西平市場－全球產業規模、佔有率、趨勢、機會和預測，按銷售管道、最終用途、地區和競爭細分，2020-2030 年

Carbamazepine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球卡馬西平市值為 8,890 萬美元，預計到 2030 年將達到 2.1734 億美元，預測期內年複合成長率(CAGR) 為 6.80%。市場正在穩步擴張，主要原因是全球癲癇、神經性疼痛和躁鬱症盛行率不斷上升。

市場概覽
預測期 2026-2030
2024年市場規模 8890萬美元
2030年市場規模 2.1734億美元
2025-2030 年複合年成長率 6.80%
成長最快的領域 直接的
最大的市場 亞太

卡馬西平是一種公認的抗驚厥藥物和情緒穩定劑，仍然是治療癲癇和三叉神經痛的基石。其廣泛的治療用途和經過驗證的臨床效果使其成為神經病學和精神病護理領域的關鍵藥物產品。

競爭格局包括跨國製藥公司和區域學名藥製造商。這些市場參與者積極參與旨在最佳化藥物配方以提高生物利用度、減少給藥頻率和最大限度地減少不良影響的研究和開發。控釋和緩釋配方等創新因其能夠提高患者依從性和臨床結果而獲得了關注。

關鍵市場促進因素

全球醫療保健產業的擴張

主要市場挑戰

不良反應和安全問題

主要市場趨勢

神經系統疾病發生率不斷上升

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球卡馬西平市場的影響

第5章：全球卡馬西平市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按銷售管道（直接、間接）
    • 依最終用途（癲癇、三叉神經痛、躁鬱症、糖尿病神經病變、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美卡馬西平市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲卡馬西平市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太卡馬西平市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲卡馬西平市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲卡馬西平市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球卡馬西平市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Sthira Labs
  • Jubilant Generics Limited
  • Vemed Pharmaceuticals Private Limited
  • GODAVARI DRUGS LIMITED
  • AKS pharma chem
  • Cipla Limited
  • VARAHI INTERNATIONAL PVT. LTD
  • Sun Pharmaceutical Industries Limited
  • Racs Pharmachem India Pvt.Ltd
  • Sarian Pharmaceuticals Pvt Ltd

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28243

Global Carbamazepine Market was valued at USD 88.90 million in 2024 and is projected to reach USD 217.34 million by 2030, growing at a compound annual growth rate (CAGR) of 6.80% during the forecast period. The market is witnessing steady expansion, primarily driven by the increasing global prevalence of epilepsy, neuropathic pain, and bipolar disorder.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 88.90 Million
Market Size 2030USD 217.34 Million
CAGR 2025-20306.80%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Carbamazepine, a well-established anticonvulsant and mood stabilizer, remains a cornerstone in the treatment of seizure disorders and trigeminal neuralgia. Its broad therapeutic utility and proven clinical effectiveness have positioned it as a critical pharmaceutical product across neurology and psychiatric care segments.

The competitive landscape comprises both multinational pharmaceutical companies and regional generic drug manufacturers. These market participants are actively engaged in research and development aimed at optimizing drug formulations to enhance bioavailability, reduce dosing frequency, and minimize adverse effects. Innovations such as controlled-release and extended-release formulations have gained traction due to their ability to improve patient compliance and clinical outcomes.

Key Market Drivers

Expansion of the Global Healthcare Sector

The continued growth of the global healthcare industry-generating annual revenues surpassing USD 4 trillion-serves as a significant catalyst for the carbamazepine market. Pharmaceuticals and biotechnology represent the largest segments, contributing approximately USD 850 billion, followed by medical technology and diagnostics at over USD 400 billion.

Enhanced access to healthcare services, improved diagnostic rates, and better treatment infrastructure globally are contributing to the increased demand for carbamazepine. Its role in managing chronic neurological and psychiatric disorders aligns well with the broader shift toward more comprehensive chronic disease management, making it a vital component in modern therapeutic regimens.

Key Market Challenges

Adverse Effects and Safety Concerns

Despite its clinical utility, carbamazepine's long-term use is associated with several adverse effects that may hinder market growth. While the drug continues to be widely prescribed for conditions such as epilepsy, bipolar disorder, and neuropathic pain, its safety profile remains a concern among healthcare professionals and patients.

Common side effects-including dizziness, fatigue, nausea, and impaired coordination-can affect quality of life and patient adherence. More critically, carbamazepine has been linked to rare but severe hypersensitivity reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), particularly among individuals with certain genetic predispositions.

Regulatory agencies, especially in Asia, have introduced mandatory genetic testing (e.g., for the HLA-B*1502 allele) prior to initiating treatment, reflecting growing concerns around safety. While these measures improve patient protection, they can also complicate prescribing protocols and contribute to higher treatment costs.

Key Market Trends

Increasing Incidence of Neurological Disorders

A notable trend influencing the carbamazepine market is the rising global incidence of neurological and psychiatric conditions-including epilepsy, trigeminal neuralgia, and bipolar disorder. The increasing burden of these chronic conditions is fueling demand for reliable and long-term pharmaceutical solutions.

This trend is evident across both developed and developing markets, where advancements in diagnostic technology and growing public health awareness are leading to earlier detection and more comprehensive treatment of neurological disorders. As a result, carbamazepine continues to play a central role in the therapeutic landscape, reinforcing its importance and market potential.

Key Market Players

  • Sthira Labs
  • Jubilant Generics Limited
  • Vemed Pharmaceuticals Private Limited
  • GODAVARI DRUGS LIMITED
  • AKS pharma chem
  • Cipla Limited
  • VARAHI INTERNATIONAL PVT. LTD
  • Sun Pharmaceutical Industries Limited
  • Racs Pharmachem India Pvt.Ltd
  • Sarian Pharmaceuticals Pvt Ltd

Report Scope

In this report, the Global Carbamazepine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbamazepine Market, By Sales Channel:

  • Direct
  • Indirect

Carbamazepine Market, By End Use:

  • Epilepsy
  • Trigeminal Neuralgia
  • Bipolar Disorder
  • Diabetic Neuropathy
  • Others

Carbamazepine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbamazepine Market.

Available Customizations:

Global Carbamazepine Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Carbamazepine Market

5. Global Carbamazepine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Epilepsy, Trigeminal Neuralgia, Bipolar Disorder, Diabetic Neuropathy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Carbamazepine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carbamazepine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Carbamazepine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Carbamazepine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Carbamazepine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Carbamazepine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Carbamazepine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Carbamazepine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Carbamazepine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Carbamazepine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Carbamazepine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carbamazepine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Carbamazepine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Carbamazepine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Carbamazepine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Carbamazepine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Carbamazepine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Carbamazepine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Carbamazepine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Carbamazepine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Carbamazepine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Carbamazepine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Carbamazepine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Carbamazepine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carbamazepine Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sthira Labs
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Jubilant Generics Limited
  • 15.3. Vemed Pharmaceuticals Private Limited
  • 15.4. GODAVARI DRUGS LIMITED
  • 15.5. AKS pharma chem
  • 15.6. Cipla Limited
  • 15.7. VARAHI INTERNATIONAL PVT. LTD
  • 15.8. Sun Pharmaceutical Industries Limited
  • 15.9. Racs Pharmachem India Pvt.Ltd
  • 15.10. Sarian Pharmaceuticals Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer